Compare Schlumberger NV (SLB) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schlumberger NV vs Tango Therapeutics Inc. — how do they compare? Schlumberger NV trades at $48.78 (market cap $72.38B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Schlumberger NV is far larger — about 19.3× Tango Therapeutics Inc.'s market cap, and Schlumberger NV pays a 2.42% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Schlumberger NV for 99 Days and Tango Therapeutics Inc. for 0 Days on average.
| SLB | TNGX | |
|---|---|---|
Market Cap | $72.38B | $3.75B |
Volume | 10,231,115 | 9,619,106 |
Sector | Energy | Health |
52-Week High | $60.10 | $32.90 |
52-Week Low | $32.57 | $7.50 |
Typical Hold Time | 99 Days | 0 Days |
Enterprise Value | $81.11B | $2.77B |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLB trades at $48.77, showing stable performance with no recent price movement. The stock demonstrates strong fundamental metrics including a 23.79 P/E ratio and 8.53% net income margin, supported by consistent earnings beats in recent quarters. Recent contract wins in Saudi Arabia, Oman, and Mozambique expand the company's international footprint and revenue visibility. Technical indicators show bearish momentum with the price near key support levels at $48.
SLB presents a compelling investment case with strong analyst support (84.85% buy rating) and a $64.58 consensus price target representing 32% upside potential. However, declining profit margins from 12.68% in 2023 to 8.52% projected for 2026 and bearish technical signals warrant caution. The company's expanding contract portfolio provides revenue stability, but investors should monitor margin pressures and oil market volatility.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
